Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CANTATA-SU
2009-009320-36Phase 3Completed
- Sponsor
- Johnson & Johnson
- Start
- Jun 2009
- Modality
- Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of canagliflozin, glimepiride and metformin in type 2 diabetes mellitus (T2DM) (3 arms), sponsored by Johnson & Johnson. Primary endpoint: Change in HbA1c from baseline through Week 52. Started Jun 2009; status: completed.
02
Drugs
canagliflozinglimepiridemetformin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2009-009320-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-009320-36.